Home / Business and Economy / Pharma Giants Buy Big to Beat Patent Cliff
Pharma Giants Buy Big to Beat Patent Cliff
5 Jun
Summary
- Pharma firms are acquiring companies to replace drugs losing patent protection.
- Mergers and acquisitions deal value reached $106 billion by early June.
- Average deal size increased to $527.3 million in 2026.
Global biopharma mergers and acquisitions have seen a sharp acceleration in 2026. Through early June, deal value has reached $106 billion across 201 transactions. This pace suggests the sector could exceed $250 billion in total deal value for the full year, marking the strongest performance since 2019. Pharmaceutical giants are aggressively pursuing acquisitions to offset looming patent expiries as major blockbuster drugs face loss of exclusivity.
Companies are strategically expanding their portfolios by acquiring new drugs or supplementing existing therapeutic areas. Activity has shifted towards "bolt-on" acquisitions in the $1 billion to $5 billion range, rather than mega-mergers. The average deal size has increased to $527.3 million so far in 2026, up from $365 million in 2025. Many companies are prioritizing products nearing commercialization while also investing in earlier-stage assets to access innovative new technologies.
